Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — H1 2026 Earnings Presentation
23 slides from Hikma Pharmaceuticals's earnings presentation, Aug 6, 2026
Slide 1: Hikma Pharmaceuticals PLC 2026 Interim Results
Better health. Within reach. Every day. Hikma Pharmaceuticals PLC 2026 Interim Results
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Introduction
Introduction Said Darwazah Chief Executive Officer
Slide 4: H1 in line with expectations, with disciplined execution and reinvestment
H1 in line with expectations, with disciplined execution and reinvestment driving long term growth Delivering a solid financial performance 1 Revenue up 4% to $1.7 billion; core operating profit up 9% to $405 million Increasing investment to support growth 2 18% increase in Group R&D and 10% increas
Slide 5: Group financial highlights – H1 2026
Group financial highlights – H1 2026 $1,728m $405m $463m Core1 revenue Core operating profit Core EBITDA2 $214m 128¢ Operating cash flow Core basic earnings per share 1. Core results are presented to show the underlying performance of the Group, excluding exceptional items and other adjustments set
Slide 6: Turning strategy into action
Turning strategy into action Actions taken across the Group will support long-term growth Driving commercial momentum Investing for growth ▪ Robust demand across our global portfolio ▪ Increased R&D investment: 18% YoY growth in spend, representing 5% of Group revenue ▪ 43 product launches across al
Slide 7: Financial performance
Financial performance Areb Kurdi Acting Chief Financial Officer
Slide 8: Solid financial performance with continued investment in growth
Solid financial performance with continued investment in growth Constant P&L highlights H1 2026 H1 2025 Change Group core results currency $m $m % % ▪ Revenue growth driven by strong Branded performance and continued Core revenue 1,728 1,657 4% 4% momentum across Europe, Canada and Cost of sales (95
Slide 9: Three high-quality businesses: Branded
Three high-quality businesses Branded H1 highlights: ($ million) +15% ▪ Revenue growth driven by strong demand across the (+14% cc) chronic portfolio and growth across most markets ▪ Core gross margin benefitting from ongoing focus on high value chronic and specialty medications, driving an improvin
Slide 10: Three high-quality businesses: Hikma Rx
Three high-quality businesses Hikma Rx H1 highlights: ($ million) ▪ Revenue broadly flat due to modest price erosion (1)% across the portfolio offset by recent launches and good performance from several in-line products ▪ Core gross margin up 3.6pp to 37.1%, reflecting improving mix, with a higher c
Slide 11: Three high-quality businesses: Injectables
Three high-quality businesses Injectables H1 highlights: ($ million) +0% ▪ Revenue broadly flat ▪ Steady US base business offset slightly lower specialty revenue during transition from Vanco Ready® to Tyzavan® 683 685 ▪ Good growth in Europe & ROW, with strong Core performance in Germany, Italy and
Slide 12: Cash flow, capex, and balance sheet
Cash flow, capex, and balance sheet Strong cash flow, robust balance sheet and continued capex Operating cash flow Capital expenditure ($ million) June 2025 June 2026 $200 1971 20% Operating cash flow 161 214 $180 Operating cash 169 165 10% 12% flow/revenue $160 15% $140 138 Debt and leverage 1,957
Slide 13: Capital allocation
Capital allocation Strong cash generation funds disciplined investment and shareholder returns Reinvesting for organic growth Prioritising R&D, M&A and partnerships ▪ 2026 capex of $190m–$210m (H1 26: $122m; FY25: ▪ R&D rising toward 5%–6% of revenue (2025: 4.5%; H1 $197m)1 2026: 5.0%) ▪ Manufacturi
Slide 14: Business review
Business review Said Darwazah Chief Executive Officer
Slide 15: Executing our strategy, building momentum: Branded
Executing our strategy, building momentum Branded Branded strategic priorities H1 2026 progress Acceleration of chronic health portfolio which represents close to 70% of total Grow positions in key Branded revenue in H1 2026 lifestyle diseases Key therapeutic areas such as diabetes are driving growt
Slide 16: Executing our strategy, building momentum: Hikma Rx
Executing our strategy, building momentum Hikma Rx Hikma Rx strategic priorities H1 2026 progress Defended leading inhalation / nasal positions – sustained share in Fluticasone Protect and optimise base (Rx and OTC) and Albuterol against new and expected entrants portfolio Sodium Oxybate - managing
Slide 17: Executing our strategy, building momentum: Injectables
Executing our strategy, building momentum Injectables Injectables strategic priorities H1 2026 progress Tyzavan® commercialisation – educating and supporting conversion of new and Developing a specialty existing customers; ~80% of Vanco Ready® customers fully or partially transitioned product portfo
Slide 18: Building an industry leading R&D organisation
Building an industry leading R&D organisation by strengthening capabilities and accelerating execution Our four strategic pillars to drive growth 1 2 3 4 Portfolio balance Targeted Manufacturing-driven Accelerated and value creation investment in complex differentiation development and and different
Slide 19: A strong pipeline across our three businesses
A strong pipeline across our three businesses >330 products in our pipeline >$100 billion Current market size 1 Development Launch Strategic focus areas phase timing profile to drive long-term growth • Ready-to-use formulations: global growth Long Term platform Development Filed (>2030) • Inhalation
Slide 20: 2026 Full year guidance reiterated
2026 Full year guidance reiterated Group Revenue growth: Core operating profit: 2% to 4% $720 million to $770 million Injectables Branded Hikma Rx ● Revenue growth: ● Revenue growth: ● Revenue: low single digits 6% to 8% in constant and broadly flat ● Core operating margin: reported ● Core operating
Slide 21: Thank you.
h. Thank you.
Slide 22: Appendix
Appendix
Slide 23: H1 2026 pipeline performance
H1 2026 pipeline performance Strong progress with pipeline execution, healthy pipeline for H2 and beyond Segment (Region) Submitted Approved Launched Injectables (Global) 25 22 22 MENA 18 10 8 US 4 3 5 Europe & ROW 3 9 9 Branded (MENA) 20 17 16 Rx (Global) 3 1 5 Total 48 40 43 23
Hikma Pharmaceuticals — H1 2026 Earnings Presentation on 6ix